Wheeler Bio, Inc.
Wheeler Bio is a biomanufacturing company dedicated to accelerating the translation of therapeutic innovation into clinical impact. With a focus on biologics and antibody therapeutics, Wheeler offers a comprehensive discovery-to-IND program, leveraging innovative platforms like Portable CMC® to streamline drug development, reduce costs, and improve process reliability. The company is committed to digital transformation, industry collaboration, and building a future-ready biomanufacturing ecosystem in Oklahoma City, supporting emerging biopharma companies and advancing patient access to life-changing therapies.
Industries
Nr. of Employees
medium (51-250)
Wheeler Bio, Inc.
The Ziggurat, 120 Robert S Kerr Ave., Oklahoma City, OK 73102, USA
Products
Portable CMC®
A platform designed to streamline the transition from drug discovery to clinical trials, integrating cell line development, process development, analytical development, and manufacturing services.
Cell Line Development
Services utilizing advanced technologies for the development of high-quality, scalable cell lines for drug substance preparation.
Process Development
Comprehensive solutions for developing robust manufacturing processes, including optimization and process transfer refinement strategies.
Analytical Development and Qualification
Services focused on designing and optimizing analytical methods tailored to regulatory requirements, including method qualification and validation.
Transient Protein Expression
CHO- and HEK-based transient protein expression services for rapid production of recombinant proteins, supporting early-stage drug development.
Process Characterization
Expertise in process characterization to optimize manufacturing processes and ensure compliance with FDA standards for commercialization.
Portable CMC®
A platform designed to streamline the transition from drug discovery to clinical trials, integrating cell line development, process development, analytical development, and manufacturing services.
Cell Line Development
Services utilizing advanced technologies for the development of high-quality, scalable cell lines for drug substance preparation.
Process Development
Comprehensive solutions for developing robust manufacturing processes, including optimization and process transfer refinement strategies.
Analytical Development and Qualification
Services focused on designing and optimizing analytical methods tailored to regulatory requirements, including method qualification and validation.
Transient Protein Expression
CHO- and HEK-based transient protein expression services for rapid production of recombinant proteins, supporting early-stage drug development.
Process Characterization
Expertise in process characterization to optimize manufacturing processes and ensure compliance with FDA standards for commercialization.
Services
Rapid transient CHO- and HEK-based protein expression for construct screening and generation of mg–g scale material for discovery and preclinical studies.
Mammalian CHO cell line development and genome engineering services including single-cell isolation, imaging, high-throughput clone screening, and stable production cell line generation for scalable manufacturing.
Upstream and downstream process development using DoE and high-throughput tools to create scalable, robust processes for tox and clinical supply.
Method development, qualification, stability testing, and analytical characterization to support release testing and regulatory submissions.
Formulation screening and optimization for bulk liquid formulations using DoE and machine-learning assisted approaches to meet stability requirements.
Generation and supply of preclinical/toxicity study material from development platforms or transferred client processes to support GLP studies.
Rapid transient CHO- and HEK-based protein expression for construct screening and generation of mg–g scale material for discovery and preclinical studies.
Mammalian CHO cell line development and genome engineering services including single-cell isolation, imaging, high-throughput clone screening, and stable production cell line generation for scalable manufacturing.
Upstream and downstream process development using DoE and high-throughput tools to create scalable, robust processes for tox and clinical supply.
Method development, qualification, stability testing, and analytical characterization to support release testing and regulatory submissions.
Formulation screening and optimization for bulk liquid formulations using DoE and machine-learning assisted approaches to meet stability requirements.
Generation and supply of preclinical/toxicity study material from development platforms or transferred client processes to support GLP studies.
Expertise Areas
- CMC process development for biologics
- Mammalian cell line development and genome engineering
- Protein expression and purification for discovery and preclinical supply
- Analytical method development and qualification
Key Technologies
- CHO and HEK mammalian expression systems
- Transposase-mediated stable genome integration
- Single-cell isolation and imaging
- High-throughput clone screening and miniaturized bioreactors
News & Updates
Wheeler Bio has announced an oversubscribed Series A-1 funding round to support its growth and expansion plans.
Patrick Lucy has been appointed as the new CEO of Wheeler Bio, bringing industry experience to lead the company's growth.
Wheeler Bio has licensed ATUM’s proprietary miFuc™ technology to enhance its Portable CMC platform.
Wheeler Bio’s facility has been selected as a finalist for the ISPE Facility of the Year Awards.
Wheeler Bio and Charles River Laboratories have announced a partnership to offer Portable CMC services.
An article discussing innovative approaches to biomanufacturing and CDMO services.
Wheeler Bio has announced an oversubscribed Series A-1 funding round to support its growth and expansion plans.
Patrick Lucy has been appointed as the new CEO of Wheeler Bio, bringing industry experience to lead the company's growth.
Wheeler Bio has licensed ATUM’s proprietary miFuc™ technology to enhance its Portable CMC platform.
Wheeler Bio’s facility has been selected as a finalist for the ISPE Facility of the Year Awards.
Wheeler Bio and Charles River Laboratories have announced a partnership to offer Portable CMC services.
An article discussing innovative approaches to biomanufacturing and CDMO services.